Fidelity trimmed its stake in Indegene Limited from 1.58% to 1.50%, selling 207,134 shares worth ₹11.29 crore at an average price of ₹545.25 per share.
A provider of analytics, technology, and specialized services to life science and healthcare organizations worldwide. Indegene delivers integrated solutions spanning commercial, medical, regulatory, and safety domains, combining data-driven insights with advanced technology platforms. The company serves pharmaceutical, biotech, and healthcare firms seeking to optimize operations, enhance decision-making, and improve market performance through evidence-based approaches and digital transformation.
Boston-based global active asset manager with India exposure through emerging market and India-focused funds.
